PULSE: Choosing an osteoporosis injectable after oral bisphosphonates is a real pain in the back
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Target Audience
Pharmacist
Learning Objectives
1) Identify candidates for osteoporosis treatment
2) Recall the unique characteristics of denosumab and zoledronic acid and how these impact treatment decisions
3) Develop a personal, evidence-based practice to recommend zoledronic acid or denosumab as second line osteoporosis treatment when presented with a post-menopausal woman previously treatment with oral bisphosphonates
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Caroline D. Crossey, PharmD
PGY2 Ambulatory Care Pharmacy Resident
UPMC Shadyside Family Health Center
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (CPE)
This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.